Forty-eight weeks is not a year
Read the tiers on any of its product pages and the pattern is consistent: a plan named for a number of months, and beneath it a billing interval in weeks that is four times that number. Twelve months becomes forty-eight weeks. Six becomes twenty-four. One becomes four.
Multiplying a forty-eight-week plan's per-month figure by twelve overstates what the plan charges, because the plan does not run twelve calendar months. Multiplying a four-week plan's figure by twelve understates it, because it bills thirteen times. Both errors are easy and both are invited by the names on the tiers.
Every row here is stored as non-monthly with the interval in the qualifier, so nothing on this site can print a per-month suffix beside one.
Four products, and a microdosing lane
It sells a core semaglutide plan, an advanced tirzepatide plan, a combined lane and a microdosing tirzepatide lane, each on its own page with its own ladder. The microdosing lane is the cheapest and lists a one-month tier with a billing interval and no figure beside it.
It also names a liraglutide product, which few sellers in this comparison do.
The ladder that is not the GLP-1 ladder
Each of the four GLP-1 product pages carries a second price ladder, in the same visual shape, for a different product entirely — a longevity supplement offered as an injection or as wafers. Its four tiers use the same term names and the same per-month wording.
A reader skimming, or a tool scraping, will take the wrong ladder. It is the single most likely way to publish a false price about this seller, and it renders on every one of its GLP-1 pages. A first-order discount also rides all four pages.
Enhance.MD's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $249⛔ the one-month tier, billed every FOUR WEEKS — thirteen charges a year, not twelve | September 2026source |
| Semaglutide (compounded) | $212⛔⛔ the tier the seller calls "12-month" is BILLED EVERY 48 WEEKS, which is eleven calendar months; reading $212 twelve times over a year overstates what the plan actually charges | September 2026source |
| Tirzepatide (compounded) | $329the one-month tier, billed every four weeks | September 2026source |
| Tirzepatide (compounded) | $280the "12-month" tier, billed every 48 weeks | September 2026source |
| Tirzepatide (compounded) | $169the microdosing lane's "12-month" tier, billed every 48 weeks; its one-month tier is listed as billed every four weeks with no figure printed beside it | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See Enhance.MD's current price →Good fit if
- Readers who want to know exactly how many times a year a plan will charge them.
- Buyers comparing a microdosing lane against a full-dose one from the same seller.
- People who want the billing interval printed rather than implied.
- Anyone who wants the operating company and its clinical corporations named.
Look elsewhere if
- Readers building an annual budget from a per-month figure; none of these are monthly.
- Buyers who want the microdosing one-month tier priced, since it is listed without a figure.
- Anyone who needs a named compounding pharmacy, a named clinician or a service-area list.
How this review was verified
- Re-read four product pages and the privacy policy on 7 September 2026, comparing requested to effective URLs and running a nonsense path against the host in the same run, which returned a 404.
- Recorded the billing interval printed beside every tier, and stored every row as non-monthly with that interval in the qualifier.
- Separated the second, non-GLP-1 price ladder that renders on all four pages from the GLP-1 ladder, rather than taking the lowest figures on the page.
- Read the entity names inside real sentences on the privacy policy rather than accepting a pattern match.
- Screened the brand against FDA's live warning-letter datatable with a positive control and a nonsense negative control in the same invocation; the screen returned zero matches, so the absence is measured rather than assumed.